- Home
- PHUN vs GNLX Comparison
PHUN vs GNLX Comparison
Compare PHUN & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHUN
- GNLX
- Stock Information
- Founded
- PHUN 2009
- GNLX 2001
- Country
- PHUN United States
- GNLX United States
- Employees
- PHUN N/A
- GNLX N/A
- Industry
- PHUN EDP Services
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- PHUN Technology
- GNLX Health Care
- Exchange
- PHUN Nasdaq
- GNLX Nasdaq
- Market Cap
- PHUN 89.7M
- GNLX 81.5M
- IPO Year
- PHUN N/A
- GNLX 2023
- Fundamental
- Price
- PHUN $5.37
- GNLX $2.46
- Analyst Decision
- PHUN Strong Buy
- GNLX Strong Buy
- Analyst Count
- PHUN 3
- GNLX 4
- Target Price
- PHUN $13.00
- GNLX $18.25
- AVG Volume (30 Days)
- PHUN 2.3M
- GNLX 80.9K
- Earning Date
- PHUN 03-11-2025
- GNLX 11-14-2024
- Dividend Yield
- PHUN N/A
- GNLX N/A
- EPS Growth
- PHUN N/A
- GNLX N/A
- EPS
- PHUN N/A
- GNLX N/A
- Revenue
- PHUN $3,537,000.00
- GNLX $8,000.00
- Revenue This Year
- PHUN N/A
- GNLX N/A
- Revenue Next Year
- PHUN $93.33
- GNLX N/A
- P/E Ratio
- PHUN N/A
- GNLX N/A
- Revenue Growth
- PHUN N/A
- GNLX N/A
- 52 Week Low
- PHUN $2.85
- GNLX $1.60
- 52 Week High
- PHUN $24.00
- GNLX $12.59
- Technical
- Relative Strength Index (RSI)
- PHUN 51.61
- GNLX 48.80
- Support Level
- PHUN $5.01
- GNLX $2.25
- Resistance Level
- PHUN $6.00
- GNLX $2.57
- Average True Range (ATR)
- PHUN 0.63
- GNLX 0.19
- MACD
- PHUN 0.02
- GNLX 0.01
- Stochastic Oscillator
- PHUN 28.12
- GNLX 41.18
About PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.